Discovery and clinical introduction of first-in-class imipridone ONC201

ONC201 is the founding member of a novel class of anti-cancer compounds called imipridones that is currently in Phase II clinical trials in multiple advanced cancers. Since the discovery of ONC201 as a p53-independent inducer of TRAIL gene transcription, preclinical studies have determined that ONC2...

Descripción completa

Detalles Bibliográficos
Autores principales: Allen, Joshua E., Kline, C. Leah B., Prabhu, Varun V., Wagner, Jessica, Ishizawa, Jo, Madhukar, Neel, Lev, Avital, Baumeister, Marie, Zhou, Lanlan, Lulla, Amriti, Stogniew, Martin, Schalop, Lee, Benes, Cyril, Kaufman, Howard L., Pottorf, Richard S., Nallaganchu, B. Rao, Olson, Gary L., Al-Mulla, Fahd, Duvic, Madeleine, Wu, Gen Sheng, Dicker, David T., Talekar, Mala K., Lim, Bora, Elemento, Olivier, Oster, Wolfgang, Bertino, Joseph, Flaherty, Keith, Wang, Michael L., Borthakur, Gautam, Andreeff, Michael, Stein, Mark, El-Deiry, Wafik S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342060/
https://www.ncbi.nlm.nih.gov/pubmed/27602582
http://dx.doi.org/10.18632/oncotarget.11814

Ejemplares similares

Ejemplares similares